Abstract: Liver cancer is a common malignant disease in China, while the primary hepatic neuroendocrine tumor (PHNET) is extremely rare presented with various manifestations. We herein describe an interesting PHNET case, which was clinically diagnosed as hepatocellular carcinoma (HCC) based on strong clinical evidence and the national guideline, but confirmed to be PHNET by pathology. A42-year-old Chinese male was admitted for persistent upper abdominal pain, and CT scan revealed a huge liver tumor in the left lobe. The tumor presented attributes of tumor rupture, portal vein tumor thrombus, elevated serum AFP level, background hepatitis B virus infection history, and radiological features mimicking typical HCC. After left semi-hepatectomy was performed for curative treatment of the primary "HCC", the pathology demonstrated the correct diagnosis be poorly differentiated neuroendocrine carcinoma (NEC). The immunohistochemistry assays showed positive neuroendocrine markers of CgA and Syn and negative HCC markers of Hep Par 1 and GPC3, ruling out concurrent HCC. This case and literature review suggest that in spite of rare incidence, PHNET should be considered as a possible diagnosis when lacking a confirmative pathology result, even when sufficient evidence of typical presentation exist to establish the clinical diagnosis of HCC.
Introduction
Liver cancer is a common malignancy in Asian countries, especially in China where a high prevalence of hepatitis B virus (HBV) infection is presented.
1,2 Among all types of liver cancer, primary hepatocellular carcinoma (HCC) is most frequent. According to the national guideline, 3 diagnosis of primary HCC could be clinically established based on radiology appearance, tumor marker level, and history of chronic liver disease. The pathological evidence is not essentially required for diagnosis. After the clinical diagnosis of HCC has been determined, the patient could receive specific healthcare against HCC, including hepatic resection, locoregional therapies like transarterial chemoembolization or ablation, and systemic targeted agents or immunotherapy. 4 In comparison to HCC, the primary hepatic neuroendocrine tumor (PHNET), as a rare subset of the neuroendocrine tumor primarily occurred in the digestive system, has a significantly lower incidence. 5 There have been frequent reports on DovePresscenters also provided cases of HCCs with neuroendocrine differentiation or mixed HCC and PHNET tumors. 5, 8, 9 To date, there has been no report of PHNET that abnormally presents with typical HCC behaviors. We herein describe an interesting and rare PHNET case, which was clinically diagnosed as HCC based on strong clinical evidence and the national guideline, but confirmed to be PHNET by pathology.
Case Presentation
A 42-year-old Chinese male was admitted to our hospital for persistent upper abdominal pain. The patient had an abrupt episode of subxiphoid pain, which lasted for half an hour and eventually relieved. He recalled a maximum pain scale as 4/10 according to the Wong-Baker Faces Pain Rating Scale system. He immediately received an emergent CT scan to show a huge liver tumor (14.0 cm × 9.7 cm × 7.7 cm) in the left lobe, with involvement of left branch of the portal vein and left hepatic artery ( Figure 1 ). The CT also indicated concurrent hemorrhage from the liver tumor, causing a small amount of free blood collection in the pelvic cavity. The hemoglobin level was 13.4 g/dL, but the α-fetoprotein (AFP) and neuron specific enolase (NSE) notably elevated to 384 ng/mL and 151 ng/mL, respectively, while the other tumor markers were in normal range. Routine contrasted MRI scan ruled out intrahepatic spread of the liver cancer, and supported the initial diagnosis of HCC. Considering that the patient had a long-term history of chronic hepatitis B infection, we established the initial diagnosis of ruptured HCC.
The patient refused surgical treatment or transarterial chemoembolization at first, and received proton pump inhibitor (PPI), terlipressin, hepatoprotective agents, antiviral therapy, and other best supportive care. Further blood test results revealed a high viral load of 1.32 × 10 4 copies per mL and Pugh-Child class A. Unfortunately, his hemoglobin and platelet levels gradually decreased to 12.6 g/dL and 84,000/μL, respectively, without any abnormal change of the vital signs. The AFP and NSE levels reached 1016 ng/mL and 172 ng/mL, respectively. The upper abdominal pain persistently existed due to untreated liver disease. One month later, the patient had a second CT scan to find the tumor size increased rapidly to 17.1 cm × 11.2 cm × 8.9 cm within the past month ( Figure 2 ). He then decided to receive surgical treatment.
An open left semi-hepatectomy with regional lymph node dissection was successfully performed. Gross dissection of the resected sample showed a huge tumor with left portal vein tumor thrombus (PVTT), and confirmed hemorrhage from the ruptured tumor, highly resembling the presentation of HCC (Figure 3 ). Inside the white and raw fish-like liver mass existed 
Discussions
Current report presents a rare, and so far the first, case of PHNET mimicking typical ruptured HCC. Although NECs of the digestive system might exhibit various behaviors, 6, 7 a confusing scenario to establish the correct diagnosis, like this case, has never been seen before, which raised our interests in two major aspects. Firstly, the liver NEC had an HCC-like radiological presentation complicated by typical HCC behaviors such as PVTT and tumor rupture, with the background HBV infection and AFP elevation. The diagnosis of primary HCC could be established according to the 2017 National Guideline for Diagnosis and Treatment of Primary HCC in China, 3 mainly based on epidemiological data from the large HBV-positive population in China. This exceptional misdiagnosis example indicates a rare probability of diagnosis inaccuracy and the confirmative role of pathological evidence. Secondly, a significantly elevated serum AFP level was observed preoperatively, but the immunohistochemistry clearly showed uniform NEC rather than HCC with neuroendocrine component. Notably, the characterization of HCC-specific markers like Hep Par 1 and GPC3 were both negative, which ruled out the possibility of concurrent existence of HCC and NEC. The elevated AFP level and positive AFP immunohistochemistry outcome might be caused by secretion of AFP by other immature or hepatoblast-like hepatocytes other than HCC cells, 10 since AFP is also a clinical marker of progenitor cell induction in injured or fibrotic liver.
11,12
The final diagnosis was poorly differentiated PHNET (WHO grade G3). Previous publications have shown that PHNET, with an extremely rare percentage of 0.38% among all liver tumors, 5 could exhibit diverse clinical manifestations, including abdominal pain, weight loss, jaundice, fatigue, and diarrhea. 6, 7 Immunohistochemically, most PHNET cases were reported to be strongly positive for CgA (67-100%) and Syn (92-100%). 5, [13] [14] [15] Several pieces of literature provided detailed serum AFP level in PHNET patients, mostly in normal range from 1.2 to 4.8 ng/mL, only one case with highly elevated AFP of 7397 IU/mL (8950 ng/mL). 7, 13, 15 Notably, the PHNET case with significant AFP elevation showed a high tumor grade of G3 and a poor prognosis with 0.7-month survival, but no further mechanism analysis was performed. 15 Another differential diagnosis in this case is HCC with neuroendocrine component or mixed tumor of HCC and NEC. Similar cases have been frequently reported. 5, 8, 9 The immunohistochemistry analysis with negative staining of hepatocyte markers Hep Par 1 and GPC3, however, unquestionably oppose this differential diagnosis. A preoperative octreotide scan might help to establish the diagnosis of NEC. Another differential diagnosis is metastatic NEC of unknown origins, which has a relatively low incidence rate consisting 10-13% of the all neuroendocrine neoplasms. 16, 17 The common sites of primary NEC with liver metastases are in the intestinal tract or the pancreas, where either endoscopic studies or abdominal CT scan showed negative results. A further PET scan or somatostatin receptor imaging should be a suitable option to identify other possible NEC origins, but the patient refused the test due to concerns of excessive radiation.
There are several limitations in the treatment course. Firstly, AFP-producing neuroendocrine tumor, though rarely occurred, should also be a possible diagnosis because of the elevated NSE level. However, our multidisciplinary tumor board preferred the initial diagnosis of HCC rather than PHNET, after considering the imaging characteristics, tumor behaviors, chronic hepatitis history, elevated AFP level, and the epidemiological incidence rate. The preoperative misdiagnosis suggests that neuroendocrine malignancies be a differential diagnosis in the liver tumor patients with NSE elevation. Secondly, a somatostatin receptor-based imaging or PET scan is vital for confirmation of the PHPET diagnosis and staging. The patient refused to have the PET scan before the surgery and somatostatin receptor scan after the histological diagnosis, worrying excessive radiation. A better communication and patient education are therefore needed for better patient obedience and diagnostic accuracy.
In conclusion, a malignant PHNET case with rare tumor behaviors similar to HCC led to preoperative misdiagnosis. Even typical presentations could be deceiving especially when the possibility of NEC diagnosis has been raised, which should be carefully reviewed and identified by physicians. It is better to establish the final diagnosis of HCC with confirmative pathological evidence when conditions permit.
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